Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMO Stock Forecast 2026-2027
$0.18
Current Price
$55.93M
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SGMO Price Targets
+5,530.6%
To High Target of $10.00
+1,026.1%
To Median Target of $2.00
+463.1%
To Low Target of $1.00
SGMO Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-64.0%
1 Year Change
-57.1%
Year-to-Date Change
-76.9%
From 52W High of $0.77
+48.0%
From 52W Low of $0.12
📊 TOP ANALYST CALLS
Did SGMO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sangamo is one of their latest high-conviction picks.
Latest SGMO Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, SGMO has a neutral consensus with a median price target of $2.00 (ranging from $1.00 to $10.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $0.18, the median forecast implies a 1,026.1% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 5,530.6% upside. Conversely, the most conservative target is provided by Gena Wang at Barclays, suggesting a 463.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMO Analyst Ratings
2
Buy
2
Hold
0
Sell
SGMO Price Target Range
Low
$1.00
Average
$2.00
High
$10.00
Current: $0.18
Latest SGMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $10.00 |
| Nov 7, 2025 | Barclays | Gena Wang | Equal-Weight | Downgrade | $1.00 |
| Sep 4, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $10.00 |
| Jun 24, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| May 14, 2025 | Barclays | Gena Wang | Overweight | Maintains | $5.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Mar 18, 2025 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $2.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Jan 23, 2025 | Truist Securities | Nicole Germino | Buy | Maintains | $5.00 |
| Jan 2, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 31, 2024 | Jefferies | Maury Raycroft | Buy | Maintains | $3.00 |
| Dec 31, 2024 | Wells Fargo | Jim Birchenough | Equal-Weight | Maintains | $2.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
| Nov 14, 2024 | Barclays | Gena Wang | Overweight | Maintains | $9.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $10.00 |
| Oct 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Oct 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Sangamo Therapeutics Inc. (SGMO) Competitors
The following stocks are similar to Sangamo based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sangamo Therapeutics Inc. (SGMO) Financial Data
Sangamo Therapeutics Inc. has a market capitalization of $55.93M with a P/E ratio of -0.4x. The company generates $39.55M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +88.4% quarter-over-quarter, while maintaining an operating margin of -175.5% and return on equity of -2,891.8%.
Valuation Metrics
Market Cap
$55.93M
Enterprise Value
$61.77M
P/E Ratio
-0.4x
PEG Ratio
N/A
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+88.4%
Gross Margin
N/A
Operating Margin
-175.5%
Net Margin
0.0%
EPS Growth
+88.4%
Financial Health
Cash/Price Ratio
+28.7%
Current Ratio
0.8x
Debt/Equity
-1.9x
ROE
-2,891.8%
ROA
-83.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sangamo Therapeutics Inc. (SGMO) Business Model
About Sangamo Therapeutics Inc.
What They Do
Develops gene therapies for serious diseases.
Business Model
Sangamo Therapeutics operates as a clinical-stage company that translates genomic technologies into therapies. It generates revenue through partnerships with major biopharma companies and potentially through the commercialization of its innovative gene and cell therapies as they progress through clinical trials.
Additional Information
The company is focused on treating conditions such as Fabry disease, hemophilia A, and preventing kidney transplant rejection. Their key products include ST-920, TX200, and SB-525, with ongoing collaborations with industry leaders like Pfizer, Novartis, and Sanofi to enhance their research and development capabilities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
183
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Country
United States
IPO Year
2000
Website
www.sangamo.comSangamo Therapeutics Inc. (SGMO) Latest News & Analysis
Latest News
Quick Summary
Sangamo Therapeutics is undergoing voluntary Chapter 11 reorganization to sell assets, with Lilly and Astellas as bidders. DIP financing secured for ongoing operations.
Why It Matters
Sangamo's Chapter 11 reorganization and asset sales to Lilly and Astellas signal strategic shifts and potential value recovery, affecting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
1 month ago
Quick Summary
Sangamo Therapeutics has hired Raymond James as a financial advisor to explore strategic alternatives for advancing its pipeline and maximizing stakeholder value.
Why It Matters
Sangamo Therapeutics hiring Raymond James signals potential strategic shifts, which could impact stock performance and investor value based on the evaluation of its pipeline and resources.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics, Inc. (SGMO) has released its Q1 2026 earnings call transcript, providing insights into the company's financial performance and strategic developments.
Why It Matters
Sangamo's Q1 2026 earnings call provides insights on financial performance, pipeline developments, and market strategy, affecting stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
1 month ago
Quick Summary
A Biologics License Agreement (BLA) for ST-920 is being submitted to the FDA. Six sites are now active in the Phase 1/2 STAND study for ST-503 targeting chronic neuropathic pain.
Why It Matters
The progress of the BLA for ST-920 and the activation of Phase 1/2 study for ST-503 indicate potential advancements in treatment options, impacting the company's valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sangamo Therapeutics reported a quarterly loss of $0.08 per share, worse than the expected loss of $0.04, but an improvement from a loss of $0.14 per share a year prior.
Why It Matters
The larger-than-expected quarterly loss signals potential challenges in Sangamo's performance, affecting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Sangamo Therapeutics (Nasdaq: SGMO) will present three abstracts at the ASGCT Annual Meeting from May 11-15, 2026, in Boston and virtually, highlighting its genomic medicine developments.
Why It Matters
Sangamo's acceptance of three abstracts at a prestigious gene therapy conference highlights its innovation and potential, which may attract investor interest and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SGMO Stock
What is Sangamo Therapeutics Inc.'s (SGMO) stock forecast for 2027?
Based on our analysis of 12 Wall Street analysts, Sangamo Therapeutics Inc. (SGMO) has a median price target of $2.00. The highest price target is $10.00 and the lowest is $1.00.
Is SGMO stock a good investment in 2027?
According to current analyst ratings, SGMO has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMO stock?
Wall Street analysts predict SGMO stock could reach $2.00 in the next 12 months. This represents a 1,026.1% increase from the current price of $0.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sangamo Therapeutics Inc.'s business model?
Sangamo Therapeutics operates as a clinical-stage company that translates genomic technologies into therapies. It generates revenue through partnerships with major biopharma companies and potentially through the commercialization of its innovative gene and cell therapies as they progress through clinical trials.
What is the highest forecasted price for SGMO Sangamo Therapeutics Inc.?
The highest price target for SGMO is $10.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 5,530.6% increase from the current price of $0.18.
What is the lowest forecasted price for SGMO Sangamo Therapeutics Inc.?
The lowest price target for SGMO is $1.00 from Gena Wang at Barclays, which represents a 463.1% increase from the current price of $0.18.
What is the overall SGMO consensus from analysts for Sangamo Therapeutics Inc.?
The overall analyst consensus for SGMO is neutral. Out of 12 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are SGMO stock price projections?
Stock price projections, including those for Sangamo Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2026 3:05 PM UTC